Literature DB >> 8816128

Natural history of perinatal hepatitis C virus infection.

E Palomba1, P Manzini, P Fiammengo, P Maderni, G Saracco, P A Tovo.   

Abstract

In order to outline the natural course of perinatal hepatitis C virus (HCV) infection, we prospectively followed seven HCV-positive children for a mean period of 65.1 months (range, 26-90 months). Physical examination findings, growth, and bilirubin and immunoglobulin levels were constantly normal. All children were still viremic at last analysis. HCV-RNA was almost constantly detected throughout follow-up, with the exception of the first days of life. All children had initial increases (of variable duration) in alanine aminotransferase values: four children subsequently had normal or borderline values for years, with exacerbation of inflammatory activity in two cases. IgM antibodies to HCV were found in three of the seven patients. Autoantibodies developed in two children. Liver biopsy, performed on five patients, documented different degrees of chronic persistent hepatitis. Thus, recovery from perinatal HCV infection seems unlikely, and chronic hepatitis develops in most infected children, including those with prolonged intervals of remission of inflammatory activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8816128     DOI: 10.1093/clinids/23.1.47

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

Review 1.  Hepatitis C in pregnancy.

Authors:  N Hadzić
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-05       Impact factor: 5.747

2.  Detection of TT virus DNA and GB virus type C/Hepatitis G virus RNA in serum and breast milk: determination of mother-to-child transmission.

Authors:  M Schröter; S Polywka; B Zöllner; P Schäfer; R Laufs; H H Feucht
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Spontaneous clearance of hepatitis C virus in vertically infected children.

Authors:  Susan Farmand; Stefan Wirth; Helga Löffler; Tanja Woltering; Sybille Kenzel; Elke Lainka; Philipp Henneke
Journal:  Eur J Pediatr       Date:  2011-07-07       Impact factor: 3.183

Review 4.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

Review 5.  Vertical hepatitis C virus transmission: Main questions and answers.

Authors:  Grazia Tosone; Alberto Enrico Maraolo; Silvia Mascolo; Giulia Palmiero; Orsola Tambaro; Raffaele Orlando
Journal:  World J Hepatol       Date:  2014-08-27

Review 6.  Vertical transmission of hepatitis C virus: Current knowledge and perspectives.

Authors:  Chun-Yan Yeung; Hung-Chang Lee; Wai-Tao Chan; Chun-Bin Jiang; Szu-Wen Chang; Chih-Kuang Chuang
Journal:  World J Hepatol       Date:  2014-09-27

7.  Use of polymerase chain reaction and antibody tests in the diagnosis of vertically transmitted hepatitis C virus infection.

Authors:  S L Thomas; M L Newell; C S Peckham; A E Ades; A J Hall
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-10       Impact factor: 3.267

Review 8.  Perinatal hepatitis C virus infection: diagnosis and management.

Authors:  S M Davison; G Mieli-Vergani; J Sira; D A Kelly
Journal:  Arch Dis Child       Date:  2006-09       Impact factor: 3.791

9.  Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively.

Authors:  Patrizia Farci; Isabella Quinti; Stefania Farci; Harvey J Alter; Rita Strazzera; Elvia Palomba; Alessandra Coiana; Daniele Cao; Anna Maria Casadei; Ritarella Ledda; Raffaele Iorio; Angela Vegnente; Giacomo Diaz; Pier-Angelo Tovo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-17       Impact factor: 11.205

10.  Vertical transmission of hepatitis C virus: a tale of multiple outcomes.

Authors:  Alejandro Escobar-Gutiérrez; Hugo Soudeyns; Ariane Larouche; Juan Carlos Carpio-Pedroza; Armando Martinez-Guarneros; Carlos A Vazquez-Chacon; Salvador Fonseca-Coronado; Lilian H T Yamasaki; Karina Ruiz-Tovar; Mayra Cruz-Rivera
Journal:  Infect Genet Evol       Date:  2013-10-18       Impact factor: 3.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.